NYSEConsumer StaplesTobaccoSnapshot 2026-07-23
Reading TPB? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity in the Consumer Staples sector. The current thesis state is cautious, as recent financial performance has been neutral and there are elevated risks to consider.
The market seems to have priced in a low level of fragility due to weak execution quality, but it does not reflect the full extent of potential turbulence. Valuation is aligned with peers, suggesting that expectations are modest.
Management has shown a commitment to increasing Modern Oral sales, which have already seen growth. However, the earnings quality remains fragile, and there is a low probability of missing expectations in the near term.
The long-term thesis hinges on management's ability to maintain guidance and deliver on sales growth. Additionally, external factors such as inflation trends and the performance of sector leaders will be crucial.
Over the next 1 to 3 years, TPB's performance will depend on management execution and external market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if the company continues to perform well after the recent earnings beat.
Confirms one read:Q2 earnings beat analyst expectations. Revenue grows over 10% compared to last year.
Confirms the other:Q2 earnings miss analyst expectations. Revenue grows under 5% compared to last year.
Why it matters: An increase in guidance shows management's confidence in growth. It can drive stock interest.
Confirms:Management raises sales guidance for Modern Oral. It is now over $300 million for FY 2026.
Disproves:Management keeps sales guidance for Modern Oral. It is under $280 million for FY 2026.
Why it matters: The FOMC's choice can change interest rates. This affects how much people spend. It also impacts Turning Point's market.
Confirms one read:When the FOMC raises rates, it shows they trust the economy.
Confirms the other:When the FOMC cuts rates or keeps them the same, it shows worries about the economy.
Why it matters: This report gives insight into consumer spending trends. Strong retail sales could boost Turning Point's outlook.
Confirms one read:Retail sales increase more than 0.5% month over month.
Confirms the other:Retail sales decline or grow less than 0.5% month over month.
Why it matters: If revenue growth picks up, it signals a positive shift in company momentum. This could improve investor confidence.
Confirms:Revenue growth in Q3 exceeds 4% year over year.
Disproves:Revenue growth remains below 4% year over year.
Why it matters: New EBITDA guidance shows management cares about making money. It can affect investor trust.
Confirms:Management gives EBITDA guidance for FY 2026. It is over $70 million.
Disproves:Management does not give any EBITDA guidance for FY 2026.
Why it matters: A continued decline in Zig-Zag sales may signal deeper issues in the product line.
Confirms:Zig-Zag segment net sales decrease more than 22% year over year in Q2.
Disproves:Zig-Zag segment net sales stabilize or grow year over year.
